1. 1B-tekst omalizumab (Xolair®) via: www.cbg-meb.nl, Geneesmiddeleninformatiebank.
2. CFH-rapport omalizumab (Xolair®) via: www.cvz.nl, CFH-rapporten.
3. Humbert M, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-316.
4. Vignola AM, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis. SOLAR. Allergy 2004; 59: 709-717.
5. Holgate S, et al. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001; 17: 233-240.
6. Productinformatie omalizumab (Xolair®) via: www.emea.europe.eu.int, human medicines, EPARs.